Plant-based Hemostat Powder Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (1g, 3g, 5g, Others), By Application (Surgical Wound Care, General Wound Care), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 204.59 MIllion
CAGR (2026-2031)	9.78%
Fastest Growing Segment	Surgical Wound Care
Largest Market	North America
Market Size (2031)	USD 358.12 MIllion

Market Overview

The Global Plant-based Hemostat Powder Market will grow from USD 204.59 MIllion in 2025 to USD 358.12 MIllion by 2031 at a 9.78% CAGR. Plant-based hemostat powders are absorbable, biocompatible surgical adjuncts derived from polysaccharides such as potato starch or oxidized cellulose, designed to accelerate the natural clotting cascade and control capillary, venous, and arteriolar bleeding. The primary drivers supporting this market include the escalating volume of complex surgical interventions and the rising global prevalence of chronic diseases requiring operative management, which necessitates effective intraoperative bleeding control to minimize complications. According to MedTech Europe, in 2024, over 63 million surgical procedures were performed across the European region, highlighting the substantial demand for essential medical technologies that ensure procedural safety and efficiency.

However, a significant challenge impeding market expansion is the stringent regulatory landscape governing these Class III medical devices, particularly regarding safety and efficacy data. The rigorous clinical evidence required to navigate complex compliance frameworks, such as the European Union Medical Device Regulation, creates high barriers to entry and prolongs approval timelines. This regulatory burden can significantly delay the commercialization of new plant-based hemostatic solutions and increase development costs for manufacturers, limiting the speed at which these products reach the healthcare sector.

Key Market Drivers

The Rising Global Volume of Surgical Procedures and Trauma Cases stands as a foundational driver for the plant-based hemostat powder market. As healthcare providers face mounting pressure to manage acute injuries and reduce elective surgery backlogs, the utilization of these biocompatible, absorbable agents has surged. Plant-based powders are particularly essential in high-volume trauma settings for their rapid ability to dehydrate blood and accelerate clotting without the viral risks associated with animal-derived products. Highlighting the scale of these critical care requirements, according to the World Health Organization, June 2024, in the 'Injuries and violence' key facts, injuries account for 4.4 million deaths annually worldwide, creating a massive necessity for effective hemorrhage control devices. Additionally, the sheer volume of pending operations amplifies this demand; according to NHS England, October 2024, in the 'Consultant-led Referral to Treatment Waiting Times' statistics, the waiting list for non-emergency hospital treatment reached 7.6 million pathways by August 2024, signaling a robust pipeline of procedures requiring surgical consumables.

Concurrently, the Increasing Adoption in Minimally Invasive and Robotic Surgeries is accelerating the preference for powder-based formulations over traditional textiles. These flowable agents are uniquely suited for laparoscopic environments, as they can be precisely delivered through narrow trocars to cover irregular bleeding surfaces in hard-to-reach anatomical cavities. This technical alignment is driving significant market growth as robotic platforms expand. According to Intuitive Surgical, October 2024, in the 'Q3 2024 Earnings Release', the volume of worldwide da Vinci procedures increased by approximately 18% compared to the same quarter in the previous year, demonstrating the expanding footprint of robotic platforms that rely on versatile, easy-to-apply adjuncts like plant-based hemostatic powders.

Download Free Sample Report

Key Market Challenges

Stringent regulatory requirements regarding safety and efficacy constitute a primary obstacle hampering the growth of the plant-based hemostat powder market. As these products are generally classified as Class III medical devices due to their absorbable nature and direct interaction with the bloodstream, they undergo rigorous scrutiny to ensure biocompatibility. Manufacturers must navigate complex compliance frameworks that demand extensive clinical evidence, which significantly increases development costs and resource allocation. This financial and operational burden creates high barriers to entry, often discouraging smaller companies from entering the space and stifling the pace of innovation within the sector.

The direct consequence of these regulatory hurdles is a marked delay in product commercialization. According to MedTech Europe, in 2024, the time required to certify high-risk medical devices under the Medical Device Regulation averaged nearly 18 months due to capacity constraints among notified bodies. Such prolonged approval timelines postpone the introduction of new hemostatic solutions to the healthcare sector, limiting manufacturers' ability to generate revenue and address immediate clinical needs efficiently.

Key Market Trends

The Development of Specialized Endoscopic Spray Delivery Systems is significantly advancing the market by enabling the non-invasive application of plant-based powders for gastrointestinal procedures. Manufacturers are engineering catheter-based devices that traverse standard endoscopes to deliver polysaccharide powders directly onto irregular bleeding sites within the GI tract, addressing the limitations of mechanical clips in moist, tortuous anatomies. This innovation allows for the rapid management of capillary bleeds following polypectomies or in peptic ulcers without the need for open or laparoscopic intervention. Validating this expansion into endoscopic utilization, according to Olympus Corporation, March 2024, in the 'Olympus Distribution of EndoClot Showing Steady Adoption in the U.S.' press release, the company’s plant-based hemostatic spray technology is now deployed across 49 U.S. states with over 5,000 kits shipped, underscoring the rapid clinical integration of these flowable solutions in gastroenterology.

Concurrently, the Incorporation of Antimicrobial Properties in Plant-based Formulations is gaining traction as healthcare providers seek to mitigate surgical site infections (SSIs) while controlling hemorrhage. Market players are enhancing starch and cellulose-derived powders with biocompatible antimicrobial agents to create dual-action devices that not only accelerate clotting but also inhibit bacterial colonization at the wound interface. This trend is a direct response to the escalating clinical and economic burden of hospital-acquired infections, which drives the demand for adjuncts that support sterile safety protocols. Highlighting the critical necessity of such preventive measures, according to the World Health Organization, November 2024, in the 'Global report on infection prevention and control 2024', effective infection prevention interventions could avert up to 821,000 deaths annually by 2050, creating a strong impetus for the adoption of hemostats that actively reduce infection risks.

Segmental Insights

The Surgical Wound Care segment is recognized as the fastest-growing category within the Global Plant-based Hemostat Powder Market due to the rising volume of invasive procedures requiring efficient bleeding management. This expansion is driven by a clinical shift toward biocompatible agents that fully absorb into the body, thereby minimizing the risk of post-operative infections or foreign body reactions. Furthermore, continued product clearances by regulatory authorities such as the US Food and Drug Administration validate the safety profiles of these devices. Consequently, hospitals are increasingly adopting these plant-derived solutions to enhance patient safety during complex operations.

Regional Insights

North America maintains a leading position in the global plant-based hemostat powder market, driven by a developed healthcare infrastructure and a high volume of surgical procedures. The region benefits from clear regulatory guidelines enforced by the U.S. Food and Drug Administration, which facilitate the approval and adoption of hemostatic medical devices. Additionally, the rising incidence of chronic diseases and trauma cases creates consistent demand for reliable bleeding control solutions during operations. The concentration of major manufacturers within this geography further secures the region's status as a primary market hub.

Recent Developments

• In October 2024, BioCer Entwicklungs-GmbH presented its plant-based hemostatic powder, HaemoCer, at the 38th EACTS (European Association for Cardio-Thoracic Surgery) Annual Meeting in Lisbon. The company showcased the efficacy of its polycharide-based hemostat technology to surgeons and medical professionals attending the congress. The presentation highlighted the product's ability to achieve rapid hemostasis and its biocompatibility in cardio-thoracic applications. This participation underscored the company's commitment to advancing the adoption of plant-based hemostatic powders in specialized surgical fields across the European market.
• In September 2024, BioCare Group (M) Sdn Bhd launched 4DryField PH, a plant-based hemostatic powder, in Mumbai, India. The launch event, organized by Biodis Pharmaceuticals Pvt. Ltd., presented the product as a solution for providing hemostasis and preventing adhesions in gynecological surgeries. 4DryField PH is a starch-based medical device that absorbs water from blood to accelerate the clotting process and forms a barrier to separate tissues during healing. This development marked a significant expansion of the product's availability in the Asian market, addressing the need for effective hemostatic agents in complex surgical procedures.
• In June 2024, Aegis Lifesciences introduced Surgi-ORC Powder, a new absorbable hemostat derived from natural, plant-based oxidized regenerated cellulose. The company announced the addition of this powder format to its hemostatic product line to address perioperative bleeding more efficiently. The product was designed to control continuous bleeding on broad surfaces and is suitable for use in both open and laparoscopic procedures. The powder is supplied in a prefilled bellows applicator, which facilitates direct dispensing onto the target bleeding site, and is intended to offer antibacterial properties and minimal tissue reaction.
• In April 2024, LifeScience PLUS officially introduced a new hemostatic wound healing solution known as DonorSeal during the 56th Annual American Burn Association Meeting in Chicago. This product is described as a 100% natural, plant-based cellulose matrix designed to control hemorrhage rapidly, reduce blood loss, and promote tissue regeneration at donor sites. The company highlighted that the device transforms into a translucent gel upon contact with blood, creating a moist environment conducive to healing. This launch expanded the company's portfolio of plant-based hemostatic technologies, which are utilized in various surgical and wound care settings.

Key Market Players

• Ethicon Inc.
• Baxter International Inc
• Becton Dickinson & Co
• Bioceres SA
• Grena AS/Norway
• PlantTec Medical GmbH
• Starch Medical Inc
• Theracion Biomedical
• Singclean Medical
• Hemostasis, LLC

By Type	By Application	By Region
1g 3g 5g Others	Surgical Wound Care General Wound Care	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Plant-based Hemostat Powder Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Plant-based Hemostat Powder Market , By Type:

• 1g
• 3g
• 5g
• Others

• Plant-based Hemostat Powder Market , By Application:

• Surgical Wound Care
• General Wound Care

• Plant-based Hemostat Powder Market , By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE